

AGENDA

7:30am NETWORKING BREAKFAST

8:00am WELCOME

Jim Palma
CEO, TargetCancer Foundation

8:30am PATIENT KEYNOTE

Zebicorn: A Rare Patient's Story
Katie Doble

8:55am SCIENTIFIC KEYNOTE

Future-Proofing Healthcare: A Vision of Patient-Centric Tissue-Agnostic Precision Medicine
Vivek Subbiah, MD
Chief, Early-Phase Drug Development, Sarah Cannon Research Institute

9:30am SESSION 1: CLINICAL TRIALS IN RARE CANCERS

On The Right TRACK- A National Decentralized Precision Genomics Trial for Rare Cancers
Razelle Kurzrock, MD
Professor of Medicine; Associate Director, Clinical Research
Founding Director, Michels Rare Cancers Research Laboratories
Froedtert and Medical College of Wisconsin

Innovative Immunotherapy Basket Trial Experience with the NCI-SWOG DART Trial
Young Kwang Chae, MD, MPH, MBA
Co-Director, Early Phase Clinical Trials Unit, Lurie Cancer Center
Associate Professor, Department of Medicine, Northwestern University Feinberg School of Medicine

10:35am MORNING BREAK

10:55am SESSION 2: HEREDITARY/GERMLINE GENETICS

The Role of Hereditary Cancer Predisposition in Precision Medicine
Catherine Skefos, MA, MS, CGC
Genetic Counselor, MD Anderson Cancer Center

Evaluation of TP53 Variants Detected on Hereditary Cancer Genetic Testing
Alison Schwartz Levine, MS, CGC
Genetic Counselor, Dana-Farber Cancer Institute

12:00pm NETWORKING LUNCH

1:00pm MOLECULAR TUMOR BOARD

TCF-001 TRACK MOLECULAR TUMOR BOARD

Razelle Kurzrock, MD, *Froedtert and Medical College of Wisconsin*

Vivek Subbiah, MD, *Sarah Cannon Research Institute*

Jacob Adashek, DO, *The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins*

Julia Elvin, MD, PhD, *Foundation Medicine*

Mina Nikanjam, MD, PhD, *University of California San Diego*

Catherine Skefos, MA, MS, CGC, *MD Anderson Cancer Center*

2:00pm SESSION 3: TUMOR AGNOSTIC THERAPIES AT 5 YEARS

Vitrakvi at 5 Years Following US Approval

Iain Webb, MD

Vice President, Head US Medical Affairs, Oncology, *Bayer*

Challenges in Implementation of Precision Oncology: Clinical Trials and Rare Tumors

Apostolia-Maria Tsimberidou, MD, PhD, FASCO, FAAAS

Professor, Department of Investigational Cancer Therapeutics

Katherine Russell Dixie Distinguished Endowed Professor

MD Anderson Cancer Center

FDA Perspective on Tissue Agnostic Cancer Drug Development

Martha Donoghue, MD

Associate Director, Pediatric Oncology and Rare Cancers, *Oncology Center of Excellence, FDA*

3:30pm AFTERNOON BREAK

4:00pm PANEL AND GUIDED DISCUSSION

Broader Distribution of Genomics and Clinical Trials to Underserved Communities

Olalekan Ajayi, PharmD, MBA

Chief Operating Officer, *Highlands Oncology Group*

President, *Association of Community Cancer Centers (ACCC)*

Jennifer Levin Carter, MD, MPH, MBA

Venture Partner, *Sandbox Industries*

Founder and CEO, *Medzown, Inc.*

Matthew Kulke, MD

Chief of Hematology/Oncology, *Boston Medical Center*

Co-Director, *BU/BMC Cancer Center*

Jens Rueter, MD

Chief Medical Officer, *The Jackson Laboratory*

Medical Director, *Maine Cancer Genomics Initiative*

5:00pm COCKTAILS AND DINNER

**2023 THINK TANK ON ADVANCING PRECISION MEDICINE IN RARE CANCERS
STEERING COMMITTEE**



Jennifer Carter, MD, MPH, MBA
Venture Partner, Sandbox Industries
Founder and CEO, Medzown, Inc.



A. John Iafrate, MD, PhD
Deputy Chair of Pathology, Massachusetts General Hospital
Professor of Pathology, Harvard Medical School



Razelle Kurzrock, MD
Professor of Medicine; Associate Director, Clinical Research
Founding Director, Michels Rare Cancers Research Laboratories
Froedtert and Medical College of Wisconsin
Principal Investigator, TCF-001 TRACK Study

THANK YOU TO OUR SPONSORS

